APR 10, 2019 10:30 AM PDT

A Sample to Insight Solution for Detection and Classification of Challenging Pathogenic BRCA Mutations

SPONSORED BY: QIAGEN
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Associate Director Global Product Management NGS, QIAGEN
    Biography
      Dr. Anika Joecker is Associate Director Global Product Management NGS at QIAGEN. She joined CLC bio (now QIAGEN) in 2011 as Senior Bioinformatician/Project & Team Manager and worked since 2013 in product management at QIAGEN - first in Bioinformatics and recently now as product manager of the GeneReader NGS System. Anika Joecker holds a Ph.D. in Biology/Bioinformatics from University of Cologne, Germany, and has worked as Bioinformatics Group Leader at the German Cancer Research Center (Heidelberg, Germany).
    • Principal Genome Scientist, Bioinformatics - Genetic Disease , QIAGEN
      Biography
        Jennifer received a B.S. in Genetics from the University of Connecticut and went on to receive a Ph.D. in Human Genetics at the Johns Hopkins School of Medicine. During her graduate training, she used Ingenuity Pathway Analysis and was so impressed with the tool that she approached QIAGEN for the opportunity to support their bioinformatics portfolio. Currently, she is the lead genome scientist supporting QIAGEN's software solutions for analysis and interpretation of variants implicated in hereditary disease.

      Abstract:

      The BRCA1 and BRCA2 genes epitomize the modern understanding of cancer molecular genetics. Today, identifying germline and somatic mutations in BRCA1/2 has become routine practice, especially for hereditary cancer studies. However, the highly-fragmented nature of traditional sample to insight workflows can make the identification and classification of all pathogenic and actionable variants in BRCA1/2 particularly challenging. In this webinar, we explore these challenges and present solutions for streamlined, standardized, and accurate detection, interpretation, and reporting of challenging BRCA mutations, such as exon-level copy number variants (CNVs), splicing variants, and variants in homopolymer regions. 

      In the first half of the webinar, we will introduce a fully-integrated Sample to Insight NGS clinical research workflow for the detection of BRCA1/2 mutations.  Designed as an integrated part of the GeneReader NGS System, the QIAact BRCA1/2 and the BRCA Advanced Panel leverages unique molecular index (UMI) technology to detect single nucleotide variants (SNVs), exon-level CNVs, even those at low-frequency, ensuring consideration of all variants within the sample. 

      In the second half of the webinar, we will present a concordance study demonstrating the accuracy of QIAGEN Clinical Insight (QCI®), QIAGEN’s clinical decision support software for the interpretation and reporting of NGS data. The study compares QCI’s automated variant classification of over 6,000 BRCA1/2 variants to the human-derived variant classifications from expert panels (the ENIGMA consortium and ClinGen). QCI achieves extremely high concordance (99.6%) and provides automated tiered classifications according to all 28 ACMG guidelines with full transparency to the underlying evidence.  


      Learning Objectives: 

      1. QIAGEN’s GeneReader workflows are pre-optimized sample to insight solutions able to overcome the challenges of a fragmented NGS workflow
      2. The BRCA ½ and the BRCA Advanced Panels coupled with the GeneReader enable comprehensive profiling of mutations within BRCA, including challenging mutations such as large Indels and exon-level CNVs, and with UMI technology, even those of low allele frequency
      3. QCI Interpret as part of the GeneReader solution automates variant classification using all 28 ACMG criteria, while transparently providing the supporting evidence for variant assessment
      4. In compelling concordance study, QCI-Interpret used to automatically classify >6000 BRCA1 and BRCA2 variants, demonstrating the extremely high concordance (99.6%) between automated tiered classification with this clinical decision support platform and classifications by a panel of experts. 


      Show Resources
      You May Also Like
      SEP 05, 2019 04:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 04:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      JUN 05, 2019 05:00 PM CEST
      C.E. CREDITS
      JUN 05, 2019 05:00 PM CEST
      DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
      AUG 27, 2019 09:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 09:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      OCT 02, 2019 11:00 AM PDT
      OCT 02, 2019 11:00 AM PDT
      DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
      JUN 26, 2019 09:00 AM PDT
      C.E. CREDITS
      JUN 26, 2019 09:00 AM PDT
      DATE: June 26, 2019TIME: 9:00am PDT, 12:00pm EDT An excessive number of software solutions are available to help manage your clinical, biobank, or biorepository sample inform...
      JUL 30, 2019 10:00 AM PDT
      C.E. CREDITS
      JUL 30, 2019 10:00 AM PDT
      DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
      Loading Comments...
      Show Resources